[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637209":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":36,"collaborators":7,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":7,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":7,"maxAge":7,"enrollmentInfo":48,"targetDuration":51,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":61,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Xiangya Hospital of Central South University","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Gong Xuan, MD.","CONTACT","0086-731-8975-3037","gong.xuan@csu.edu.cn",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"Shuwen Kuang, MD.","0086-13367494221","228102171@csu.edu.cn",[19],{"facility":5,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"RECRUITING","Changsha","Hunan","410008","China","CN",{"type":27,"coordinates":28},"Point",[29,30],112.97087,28.19874,{"lat":30,"lon":29},[33,35],{"name":34,"role":11,"phone":12,"phoneExt":7,"email":13},"Xuan Gong, MD.",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Xuan Gong","Associate Consultant","100637209","multicenter-prospective-study-on-mri-ai-model-for-midline-glioma-subtyping-and-prognosis-100637209",false,"NCT07608003","Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:","Application of MRI-Based Artificial Intelligence Models for Preoperative Molecular Subtyping and Prognostic Assessment of Midline Gliomas: A Multicenter Prospective Clinical Study","Inclusion Criteria:\n\n* Patients with diffuse gliomas were pathologically and molecularly diagnosed.\n* The clinical case data of all patients were complete.\n* Patients underwent preoperative MRI examination.\n\nExclusion Criteria:\n\n* The tumor is not located in the intracranial midline.\n* Cases in which MRI were incomplete or with significant noise and artifacts.","ALL",{"count":49,"type":50},500,"ESTIMATED","3 Years","OBSERVATIONAL","A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p\u002F19q. This prospective multicenter study will validate the model's accuracy in preoperative molecular subtyping and its value in prognostic assessment and clinical decision-making across multiple neurosurgical centers.",[55,56,57,58,59,60],"Gliomas Harboring IDH1 and\u002For IDH2 Mutations","Glioma Glioblastoma Multiforme","Glioma of Brainstem","Glioma, Diffuse Midline, H3K27M-mutant","Glioma : Oligodendroglioma or Astrocytoma","Gliomas",[62,63,64,65],"Midline gliomas","Molecular diagnosis","Foundation model","Prognosis prediction","2026-05-25",{"date":68,"type":69},"2026-05-27","ACTUAL",{"date":71,"type":50},"2026-05-10",{"date":73,"type":50},"2030-12-31",{"name":5,"class":6},1]